Kairos Pharma, Ltd.
KAPA
$0.8133
$0.02833.61%
AMEX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 17.89% | 153.96% | 192.93% | 233.47% | 237.19% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 36.41% | 146.09% | 193.61% | 240.91% | 200.18% |
| Operating Income | -36.41% | -146.09% | -193.61% | -240.91% | -200.18% |
| Income Before Tax | -43.65% | -207.98% | -147.04% | -106.97% | -72.57% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -43.65% | -207.98% | -147.04% | -106.97% | -72.57% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -43.65% | -207.98% | -147.04% | -106.97% | -72.57% |
| EBIT | -36.41% | -146.09% | -193.61% | -240.91% | -200.18% |
| EBITDA | -40.15% | -182.33% | -257.88% | -339.74% | -278.10% |
| EPS Basic | -29.14% | -198.26% | -142.69% | -102.56% | -68.74% |
| Normalized Basic EPS | -54.80% | -197.77% | -142.19% | -102.56% | -68.85% |
| EPS Diluted | -29.14% | -198.26% | -142.69% | -102.56% | -68.74% |
| Normalized Diluted EPS | -54.80% | -197.77% | -142.19% | -102.56% | -68.85% |
| Average Basic Shares Outstanding | 9.37% | 2.96% | 1.77% | 1.60% | 1.43% |
| Average Diluted Shares Outstanding | 9.37% | 2.96% | 1.77% | 1.60% | 1.43% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |